| Navarini, Alexander A |
Neo-DREAM, NCT03567889: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients |
|
|
| Recruiting | 3 | 186 | Europe, US | Daromun, Surgery, Adjuvant therapy | Philogen S.p.A. | Melanoma Stage IIIB/C | 06/24 | 06/26 | | |
NCT06319794: Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis |
|
|
| Recruiting | 2 | 40 | Europe | Bimiralisib | TORQUR | Actinic Keratosis | 12/24 | 12/24 | | |
NCT05848453: Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses |
|
|
| Completed | 1 | 24 | Europe | BAP5191 | Bacoba AG, University Hospital, Basel, Switzerland, Swiss TPH, Basel, Switzerland | Healthy | 03/24 | 03/24 | | |
| Recruiting | N/A | 40 | Europe | Self- learning software that can detect acne lesions, Patient reported outcomes | University Hospital, Basel, Switzerland | Acne Lesions, Acne Vulgaris | 12/22 | 12/22 | | |
NCT04231500: The Skin Microbiome in Graft Versus Host Disease |
|
|
| Recruiting | N/A | 60 | Europe | Skin swabs, Skin punch biopsies, additional blood sampling | University Hospital, Basel, Switzerland, Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel | Skin Microbiome, Graft Versus Host Disease, Graft Versus Host Disease in Skin | 03/26 | 03/27 | | |
| Recruiting | N/A | 3370 | Europe | Analysis of samples | University Hospital, Basel, Switzerland | Neutrophil-mediated Inflammatory Dermatoses, Inflammatory Dermatoses | 09/29 | 09/29 | | |
| Recruiting | N/A | 180 | Europe, RoW | biological sampling, Phenotypic description, Photography | University Hospital, Basel, Switzerland, Boehringer Ingelheim | Pustular Psoriasis (PP) | 12/30 | 12/30 | | |
| Recruiting | N/A | 750 | Europe | Adalimumab, Humira, Etanercept, Enbrel, Infliximab, Remicade, Ustekinumab, Stelara, Cyclosporine A, Fumaric acids, Methotrexate, Other anti-psoriatic systemic treatments | Swiss Dermatology Network for Targeted Therapies | Psoriasis | 06/32 | 06/33 | | |
| French, Lars |
| Recruiting | N/A | 180 | Europe, RoW | biological sampling, Phenotypic description, Photography | University Hospital, Basel, Switzerland, Boehringer Ingelheim | Pustular Psoriasis (PP) | 12/30 | 12/30 | | |
| Soyka, Michael |
NCT04868695: Subjective and Objective Outcome of ESS in CRSwNP |
|
|
| Recruiting | N/A | 99 | Europe | 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3 | University of Zurich | CRS | 03/25 | 03/25 | | |
| Recruiting | N/A | 35 | Europe | Infundibultomy | University of Zurich | Nasal Blockage, Nasal Obstruction, Septum; Deviation | 07/24 | 12/24 | | |
DysOSMIC, NCT06482138: Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation |
|
|
| Recruiting | N/A | 160 | Europe | Biopsy and Cytobrush | Universitaire Ziekenhuizen KU Leuven, University Hospital, Geneva, Max Planck Research Unit for Neurogenetics, University Hospital Carl Gustav Carus, University of Zurich | Covid19, Olfactory Dysfunction | 12/24 | 03/25 | | |
| Lachat, Mario |
NCT02365454: NEXUS™ Aortic Arch Stent Graft System First In Man Study |
|
|
| Completed | N/A | 18 | Europe, RoW | Stent Graft Placement (Nexus) | Endospan Ltd. | Thoracic Aortic Arch Disease, Thoracic Aortic Aneurysm | 11/18 | 06/23 | | |
ARCUS, NCT05636527: Further Evaluation of Safety and Performance of the NEXUS Aortic Arch Stent Graft System and the Custom-Made NEXUS DUO™ Aortic Arch Stent Graft System |
|
|
| Recruiting | N/A | 60 | Europe | | Endospan Ltd. | AAT9 | 07/25 | 07/30 | | |
| Chaykovska, Lyubov |
ARCUS, NCT05636527: Further Evaluation of Safety and Performance of the NEXUS Aortic Arch Stent Graft System and the Custom-Made NEXUS DUO™ Aortic Arch Stent Graft System |
|
|
| Recruiting | N/A | 60 | Europe | | Endospan Ltd. | AAT9 | 07/25 | 07/30 | | |
| Stieglitz, Lennart H |
| Terminated | N/A | 88 | Europe | Reimplantation of cryoconserved bone flap | University of Zurich | Brain Edema | 12/23 | 12/23 | | |
NCT06498349: Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl |
|
|
| Recruiting | N/A | 60 | Europe | bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment, best medical treatment for management of impulse control in Parkinson´s disease, best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations | University of Kiel, Insel Gruppe AG, University Hospital Bern, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Philipps University Marburg Medical Center, University Hospital Schleswig-Holstein, Campus Kiel, Czech Technical University in Prague, University of Pennsylvania | Parkinson Disease, Impulse Control Disorders | 07/27 | 07/28 | | |
| Recruiting | N/A | 60 | Europe | bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper, best medical treatment for manangement of impulse control in Parkinson´s disease, best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper | Steffen Paschen, Czech Technical University in Prague, Insel Gruppe AG, University Hospital Bern, Philipps University Marburg Medical Center, University Hospital Schleswig-Holstein, Campus Kiel, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) | Parkinson Disease, Impulse Control Disorder | 07/27 | 07/28 | | |
DBS-SCI, NCT03053791: Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait |
|
|
| Recruiting | N/A | 5 | Europe | Deep brain stimulation in mesencephalic locomotor region, Implantation of a Deep brain stimulation system | University of Zurich, Balgrist University Hospital, ETH Zurich, Wings for Life | Spinal Cord Injury | 12/26 | 12/27 | | |
| Alkadhi, Hatem |
NCT06305156: Protocol Optimization in CT for the Quantification of BMD |
|
|
| Recruiting | N/A | 150 | Europe | Bone Mineral Density quantification | Hatem Alkadhi | Osteoporosis, Osteopenia, Bone Loss | 03/25 | 03/25 | | |
| Recruiting | N/A | 1200 | Europe, RoW | Non Interventional | University Hospital, Bonn, European Union | Acute Cardiovascular Disease | 07/28 | 07/28 | | |
| Balermpas, Panagiotis |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
| Active, not recruiting | 2 | 180 | Europe | Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor | Goethe University, German Cancer Aid, AstraZeneca | Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II | 12/26 | 03/27 | | |
MARTHA, NCT03972072: MRI - Guided Adaptive RadioTHerapy for Reducing XerostomiA in Head and Neck Cancer (-trial) |
|
|
| Active, not recruiting | N/A | 49 | Europe | Pre-defined MR-linac based IGRT and plan adaptation protocol, salivary flow measurements | Panagiotis Balermpas | Head and Neck Cancer, Xerostomia Due to Radiotherapy | 05/25 | 05/26 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
| Maul, Tatjana |
| Recruiting | N/A | 750 | Europe | Adalimumab, Humira, Etanercept, Enbrel, Infliximab, Remicade, Ustekinumab, Stelara, Cyclosporine A, Fumaric acids, Methotrexate, Other anti-psoriatic systemic treatments | Swiss Dermatology Network for Targeted Therapies | Psoriasis | 06/32 | 06/33 | | |
